Vaxcyte, Inc. (PCVX) Operating cash flow 2018–2025
Vaxcyte, Inc. (PCVX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$655.6MFY2025 · since FY2018: -$30.5M → -$655.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$655.6M | -44.8% |
| FY2024 | -$452.6M | -52.5% |
| FY2023 | -$296.8M | -74.0% |
| FY2022 | -$170.6M | -40.5% |
| FY2021 | -$121.4M | -160.3% |
| FY2020 | -$46.6M | +1.1% |
| FY2019 | -$47.1M | -54.7% |
| FY2018 | -$30.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More PCVX financial trends
PCVX RevenuePCVX Net incomePCVX Net marginPCVX Gross profitPCVX Gross marginPCVX Operating incomePCVX Operating marginPCVX Free cash flowPCVX Capital expendituresPCVX Return on equityPCVX Stock buybacksPCVX Dividends paidPCVX Total assetsPCVX Total liabilitiesPCVX Shareholders’ equityPCVX overview →